



IBA signs contract to install Latin America's first proton therapy center in Argentina

Louvain-la-Neuve, Belgium, 21 September, 2015 - IBA (Ion Beam Applications SA), the world's leading provider of proton therapy solutions for the treatment of cancer, announces today that it has signed a contract with the company INVAP for the installation of a proton therapy center at the Instituto de Oncologia Angel Roffo hospital in Buenos Aires, Argentina.

IBA will equip the new center with its *Proteus[®]PLUS* system, including one gantry treatment room with next generation Pencil Beam Scanning capability and one research and development room. The contract will also include an operation and maintenance agreement. The equipment and services that will be supplied by IBA are worth between EUR 35 and 40 million to IBA.

This first proton therapy center to be installed in Latin America is part of the implementation of the Nuclear Medicine National Plan of the Argentine Ministry of Federal Planning, Public Investment and Services, together with the Ministry of Health and the National Atomic Energy Commission (CNEA). The Nuclear Medicine National Plan is a unique government plan of investment in infrastructure and equipment designed to ensure free access to the highest standards in prevention, treatment, research and training in nuclear medicine and oncology. It is expected that the center will treat its first patient at the end of 2018.

Olivier Legrain, Chief Executive Officer of IBA commented: "This new contract demonstrates the growing global appeal of proton therapy and IBA's continuing successful penetration of emerging markets. We are very proud to have been selected to install the first proton therapy center in Latin America and to be playing an important role in bringing such innovative cancer treatment modalities to patients in Argentina."

The Argentine Minister of Federal Planning, Public Investment and Services, Julio De Vido, commented: "Bringing an innovative new cancer center closer to the people has the objective to give better chances to fight this severe disease. Argentina is the first country in Latin America to have access to this unique medical technology which will be beneficial for the health of patients in the country."

Proton therapy is considered to be the most advanced form of targeted cancer radiotherapy due to its superior dose distribution and reduction in side effects. Over half of the proton facilities worldwide are equipped with IBA's systems.



Notes to Editors

About IBA

IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The Company is the worldwide technology leader in the field of proton therapy, the most advanced form of radiation therapy available today. IBA's proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full scale proton therapy centers as well as compact, single room systems. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry.

Headquartered in Belgium and employing about 1,100 people worldwide, IBA has installed systems across the world, from Europe and the US and to the emerging markets. IBA is listed on the pan-European stock exchange EURONEXT. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB) and more information can be found at: www.iba-worldwide.com

About INVAP

INVAP is an Argentinian company devoted to the design and construction of complex technological systems, with more than 30 years of history in the domestic market and more than twenty in the international scene. Its mission is to develop state-of-the-art technology in different industrial, scientific and applied research fields, thus creating "technological packages" with high added value, to meet domestic requirements or to be exported to international markets. www.invap.com.ar/en/

For further information please contact:

IBA

Jean-Marc Bothy
Chief Financial Officer
+32 10 475 890
Investorrelations@iba-group.com

Thomas Ralet
Vice-President Corporate Communication
+32 10 475 890
Communication@iba-group.com

For media and investor enquiries:

Consilium Strategic Communications

Amber Fennell, Matthew Neal, Ivar Milligan
+44 (0) 20 3709 5700
IBA@consilium-comms.com

Rx Communications Group (US)

Melody Carey
+ 1 917 322 2571
mcarey@RxIR.com